Related Experiment Video
Updated: Sep 22, 2025
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles
Binbin Jiao1, Kunpeng Liu2, Haitao Gong2
1Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China; Department of Urology, China-Japan Friendship Hospital, Beijing, China.
Abstract:
Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations. However, the insignificant endogenous stimulus difference between cancer cells and normal cells in most cases and the high local drug concentration make it essential to develop new drugs with broader selectivity-window. Herein, based on the statistically different NQO1 expression between cancerous and normal bladder tissues, the reactive oxygen species (ROS) activatable epirubicin prodrug and highly potent NQO1 substrate, KP372-1, was co-delivered using a GSH-responsive mucoadhesive nanocarrier. After endocytosis, epirubicin could be promptly activated by the NQO1-dependent ROS production caused by KP372-1, thus specifically inhibiting the proliferation of bladder cancer cells. Since KP372-1 is much more potent than some commonly used NQO1 substrates, for example, β-lapachone, the cascade drug activation could occur under much lower drug concentration, thus greatly lowering the toxicity in normal cells and broadening the selectivity-window during intravesical bladder cancer chemotherapy.
Insights
This study introduces a novel nanocarrier system for bladder cancer chemotherapy. It delivers an epirubicin prodrug activated by NQO1, enhancing cancer cell killing while reducing toxicity.
Area of Science:
- Biomedical Engineering
- Oncology
- Drug Delivery Systems
Background:
- Clinical intravesical chemotherapy for bladder cancer faces limitations due to toxicity and low drug residence.
- Existing treatments struggle with insufficient selectivity between cancer and normal cells, necessitating improved drug delivery strategies.
Purpose of the Study:
- To develop a novel nanocarrier system for targeted bladder cancer chemotherapy.
- To enhance the efficacy and reduce the toxicity of intravesical epirubicin treatment.
Main Methods:
- Co-delivery of a reactive oxygen species (ROS) activatable epirubicin prodrug (KP372-1) and a highly potent NQO1 substrate using a GSH-responsive mucoadhesive nanocarrier.
- Utilizing statistically different NQO1 expression in bladder tissues for targeted drug activation.
Main Results:
- The nanocarrier system demonstrated specific activation of epirubicin in cancer cells via NQO1-dependent ROS production.
- KP372-1's high potency enabled cascade drug activation at lower concentrations, significantly reducing normal cell toxicity.
- The developed system broadened the selectivity-window for intravesical bladder cancer chemotherapy.
Conclusions:
- The novel nanocarrier system effectively targets and kills bladder cancer cells by leveraging NQO1 expression and ROS-mediated drug activation.
- This approach offers a promising strategy to overcome the limitations of current intravesical chemotherapy, improving treatment safety and efficacy.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...